Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Times Interest Earned (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Times Interest Earned for 4 consecutive years, with -$18.61 as the latest value for Q3 2025.

  • On a quarterly basis, Times Interest Earned fell 2.56% to -$18.61 in Q3 2025 year-over-year; TTM through Sep 2025 was -$19.21, a 20.98% decrease, with the full-year FY2024 number at -$19.93, down 15.24% from a year prior.
  • Times Interest Earned was -$18.61 for Q3 2025 at Centessa Pharmaceuticals, up from -$18.95 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$10.7 in Q1 2025 to a low of -$41.39 in Q2 2022.
  • A 4-year average of -$21.27 and a median of -$18.89 in 2022 define the central range for Times Interest Earned.
  • Peak YoY movement for Times Interest Earned: soared 53.63% in 2023, then crashed 119.79% in 2024.
  • Centessa Pharmaceuticals' Times Interest Earned stood at -$18.89 in 2022, then grew by 27.55% to -$13.69 in 2023, then plummeted by 119.79% to -$30.08 in 2024, then skyrocketed by 38.13% to -$18.61 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Times Interest Earned are -$18.61 (Q3 2025), -$18.95 (Q2 2025), and -$10.7 (Q1 2025).